ReviewInternational journal of molecular sciences2024
A Review of the Use of Native and Engineered Probiotics for Colorectal Cancer Therapy.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Enabling Clinical Translation of Oral Probiotics Through Formulation Engineering and Scalable Manufacturing.Biotechnology journal · 2026Pooled it
- The current status and prospects of gut microbiota combined with PD-1/PD-L1 inhibitors in the treatment of colorectal cancer: a review.BMC gastroenterology · 2025Pooled it
- Integrated Genomic, Structural, and Metabolomic Profiling of Freeze-Dried Postbiotic Supernatants Reveals Multi-Target Anticancer Activity Against Caco-2 Cells.Probiotics and antimicrobial proteins · 2026Article
- A deformableMaterials today. Bio · 2026Article
- From lab to law: emerging applications, potential benefits, evolving regulatory framework and challenges for engineered probiotics.Microbial cell factories · 2026Review
- The Role of Next-Generation Probiotics in Colorectal Cancer Pathways: Mechanisms and Therapeutic Potential.Probiotics and antimicrobial proteins · 2026Review
- EngineeredAnnals of medicine and surgery (2012) · 2026Article
- Emerging risk factors and the role of gut microbiota in immunomodulation and therapeutic implications in colorectal cancer.Cancer pathogenesis and therapy · 2026Review
- Gut microbiota reshaping the pancreatic cancer immune microenvironment: new avenues for immunotherapy.Molecular cancer · 2025Review
- Molecular Mechanisms of Probiotic Action Against Gastrointestinal Cancers.International journal of molecular sciences · 2025Review
- Review
- Heavy Metal-Gut Microbiota Interactions: Probiotics Modulation and Biosensors Detection.Biosensors · 2025Review
- Gut microbiota interplay with autophagy-EMT dynamics in colorectal cancer.Frontiers in cell and developmental biology · 2025Review
- Encapsulation of Probiotics within Double/Multiple Layer Beads/Carriers: A Concise Review.Molecules (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a serious global health concern, and researchers have been investigating different strategies to prevent, treat, or support conventional therapies for CRC. This review article comprehensively covers CRC therapy involving wild-type bacteria, including probiotics and oncolytic bacteria as well as genetically modified bacteria. Given the close relationship between CRC and the gut microbiota, it is crucial to compile and present a comprehensive overview of bacterial therapies used in the context of colorectal cancer. It is evident that the use of native and engineered probiotics for colorectal cancer therapy necessitates research focused on enhancing the therapeutic properties of probiotic strains.. Genetically engineered probiotics might be designed to produce particular molecules or to target cancer cells more effectively and cure CRC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.